Introduction
Despite advances in the diagnosis and treatment of women with early breast cancer, globally more than 500,000 women die annually from the disease, reflecting the ongoing need for better treatment for women with metastatic breast cancer (MBC) (World Health Organization, 2014) . Increasingly, we appreciate the heterogeneity of MBC in terms of its biology, but when making systemic treatment decisions, there are four main subgroups: hormone receptor (HR)-positive (≥65% of invasive breast cancers), which comprise luminal A cancers that are human epidermal growth factor receptor 2 (HER2)-negative and low Ki 67 and luminal B cancers that are HER2-positive or high Ki 67; HER2-positive (15-20%); and HR-and HER2-negative or triple-negative breast cancers (TNBC; 15-20%) (Lakhani et al., 2012) . The median survival of patients with MBC is approximately 24 months, but is better in patients with HRpositive and HER2-positive tumors than those with TNBC (André and Zielinski, 2012; Kennecke et al., 2010; Bonotto et al., 2014) .
While there are major differences in the treatment of patients with MBC, chemotherapy remains fundamental to the management of women with all molecular subtypes. For those with TNBC, chemotherapy offers the only systemic treatment option, but they are not the only group in whom chemotherapy is important. Patients with HR-positive disease, the biggest MBC subgroup, usually receive successive lines of endocrine therapy as long as they respond (Fedele et al., 2012 ). Everolimus appears to delay endocrine resistance (Baselga et al., 2012) ; palbociclib also enhances the efficacy of endocrine therapy (letrozole or fulvestrant) (Finn et al., 2014) . Ultimately, when endocrine options have been exhausted, or the patient develops more aggressive disease, chemotherapy becomes relevant. Similarly, patients with HER2-positive MBC receive targeted therapies (e.g., trastuzumab, pertuzumab, lapatinib) usually in combination with chemotherapy; trastuzumab emtansine (T-DM1) is given as monotherapy, but is a conjugate that includes the cytotoxic agent maytansine (Krop et al., 2014) . Independent of the molecular phenotype, chemotherapy will, therefore, be an option at some point for most patients with MBC. Early reports of immunotherapy targeting PD-1/PD-L1 and antiandrogens are encouraging in subsets of TNBC, but these are not ready to replace chemotherapy (Emens et al., 2015; Traina et al., 2015) .
Improving overall survival (OS) and/or quality of life (QOL) are key aims in treating patients with MBC. A perception may exist when considering chemotherapy: that the choice is between efficacy with treatment or better QOL without treatment. This misconception ignores the complications of the underlying disease on QOL. Our aim should, therefore, be to improve both quantity and quality of life for women with MBC.
Another guiding principle in treating patients with MBC is that single-agent sequential treatment is usually preferable to combination treatments (Fedele et al., 2012) . The latter frequently achieves higher response rates, but at the cost of increased toxicity and little impact on OS. Although single-agent sequential treatment is accepted as "standard," the evidence from randomized trials regarding which drug to use following anthracycline and taxane has been surprisingly limited, especially for "old" agents such as vinorelbine and gemcitabine (Oostendorp et al., 2011) . As a result, guidelines do not specify the sequence in which drugs should be given.
In contrast to the use of endocrine and HER2 targeted therapies, where biomarkers predictive of efficacy (e.g., ER, HER2 status) are integral to treatment decisions, similar biomarkers are not well defined in the context of specific chemotherapy. The data are arguably strongest for patients with BRCA-mutated MBC in whom carboplatin was substantially more effective and better tolerated than docetaxel as first-line treatment (Tutt et al., 2014a) . The ability to "personalize" the choice of cytotoxic to the individual patient and her cancer more widely would represent a major paradigm shift.
Drug resistance is, without doubt, the primary impediment to successful treatment of patients with MBC (Perez, 2009) . With the increased use of anthracyclines (although with less cumulative doses) and taxanes in the (neo) adjuvant setting, a growing proportion of patients with MBC have pretreated and/or drug-resistant disease (Perez, 2009) . Usual practice after an anthracycline and taxane has been to favor agents from a class not previously administered, with the expectation that the cancer is less likely to be cross-resistant to such treatment. The need remains, therefore, for new and better chemotherapy for women with MBC, almost half (43%) of whom receive >3 lines of chemotherapy (Ribeiro et al., 2012) . New agents should preferably belong to a novel class, or have a novel mechanism of action, improve OS while maintaining or improving QOL when given as monotherapy, and be well tolerated and supported by sound evidence that would ideally include a predictive biomarker.
This article does not attempt to be a comprehensive review of chemotherapy in MBC. Rather, we focus on single-agent treatment following an anthracycline and a taxane, limiting ourselves to the most widely used drugs and emerging chemotherapy options.
Current therapeutic options for anthracycline-and taxane pretreated MBC
Until recently, therapeutic options after failure of anthracycline and taxane were limited (André and Zielinski, 2012) . Currently, widely approved monotherapies for later-line treatment of MBC include capecitabine, eribulin, nanoparticle albumin-bound (nab)-paclitaxel, and ixabepilone (in the U.S.); vinorelbine is approved after an anthracycline (but not specifically a taxane) in Europe. Pegylated liposomal doxorubicin (PLD) and single agents such as gemcitabine, platinum agents, and irinotecan are also used (Table 1) . There is no agreement regarding the preferred agents and their sequence; a recent consensus report recognized that evidence is strongest for eribulin and capecitabine (Partridge et al., 2014) . Likewise, carboplatin/cisplatin chemotherapy seems to be especially active in patients with BRCA 1/2 mutations or for TNBC with DNA repair deficiency (Isakoff et al., 2015) . The TNT randomized phase III trial compared carboplatin with docetaxel in 376 patients with metastatic/locally recurrent advanced TNBC and/or BRCA1/2 positive tumors (Tutt et al., 2014b) . In the 43 BRCA positive patients the ORR was 68% vs 33% and PFS of 6.8 vs 3.2 months in the carboplatin vs docetaxel arms, respectively. Such differences were not, however, seen in the overall population (ORR of 31.4 vs 35.6% and PFS of 3.1vs 4.5 months in the carboplatin vs docetaxel arms, respectively). Indeed, many of the current options after anthracycline and taxane have not been compared in randomized clinical trials, and cross-trial comparisons can be difficult. Consequently, treatment decisions are frequently based on personal experience, prior therapy, adverse event profiles, and patient preference (Ribeiro et al., 2012) .
Rechallenge with, or reformulation of, an anthracyclines or taxane
There is a paucity of evidence documenting the efficacy of rechallenge with a conventional anthracycline or taxane in patients with MBC (Ribeiro et al., 2012; Partridge et al., 2014; Isakoff et al., 2015; Tutt et al., 2014b; Venturini et al., 1996) . Although responses have been described, most studies are single-center cohorts, small phase II trials, or retrospective analyses of phase III studies; such trials often do not specify previous adjuvant chemotherapy, and patients with anthracycline-and taxane-resistant or refractory dis- ease may be excluded (Venturini et al., 1996; Falkson et al., 1994; Bontenbal et al., 1998; Perez et al., 2001; Valero et al., 1998) . Nevertheless, patients with disease progression after a "substantial" period following adjuvant anthracycline or taxane treatment may benefit from rechallenge with a conventional anthracycline or taxane in particular if a limited number of cycles of adjuvant anthracyclines and taxanes was received. Although cardiac toxicity can be a concern, the cumulative anthracycline dose in standard adjuvant regimens frequently leaves scope for rechallenge, especially with epirubicin (Ryberg et al., 1998) . Another strategy is to rechallenge with a novel anthracycline or taxane formulation. Most such clinical trials exclude patients with resistant or refractory disease (Table 2) (Keller et al., 2004; Al-Batran et al., 2006; Sparano et al., 2009; Gradishar et al., 2005; Blum et al., 2007a; Roy et al., 2009; Lobo et al., 2010; Gradishar et al., 2012; Rugo et al., 2015; Yardley et al., 2013; Hamilton et al., 2013; Sun et al., 2014) . It is also difficult to determine whether rechallenge of new formulations is superior to conventional formulations as data are limited, and direct comparisons were not made. Nevertheless, liposomal anthracyclines as pegylated (PLD) and non-pegylated (NPLD) doxorubicin have different pharmacokinetic profiles (i.e., longer circulating half-life, enhanced drug accumulation) from those of conventional anthracyclines and appear less cardiotoxic whilst demonstrating similar efficacy (Keller et al., 2004; Al-Batran et al., 2006; Sparano et al., 2009) . With the availability of multiple other active cytotoxics, PLD or NPLD re-challenge is, however, likely to be limited to patients with a long relapse-free interval following anthracycline-based adjuvant therapy, without significant cardiac impairment and limited access to alternative drugs. Data to support PLD or NPLD rechallenge in later lines of therapy are lacking.
Nab-paclitaxel is an albumin-based paclitaxel delivery system developed as an alternative to solvent-based taxanes and exploiting enhanced albumin uptake in tumors (Table 2) (Ribeiro et al., 2012; Gradishar et al., 2005; Blum et al., 2007a; Roy et al., 2009; Lobo et al., 2010; Gradishar et al., 2012; Rugo et al., 2015; Yardley et al., 2013; Hamilton et al., 2013; Sun et al., 2014) . Nab-paclitaxel achieved superior overall response rate (ORR) and time to tumor progression (TTP) with less myelosuppression compared to 3-weekly paclitaxel in a phase III trial (Gradishar et al., 2005) ; it also compared favorably with docetaxel in a randomized phase II trial (Gradishar et al., 2012) . In the phase III Cancer and Leukemia Group B (CALGB) 40502 study, however, nab-paclitaxel was not superior to weekly paclitaxel but did increase neurotoxicity (Rugo et al., 2015) . In terms of efficacy after failure of a conventional taxane, defined as metastatic disease progression during taxane therapy or relapse within 12 months of adjuvant taxane, responses to nab-paclitaxel have been reported (Yamamoto et al., 2011) ; other phase II/III trials have demonstrated activity (Table 2) . Despite recent disappointing results, nab-paclitaxel is certainly an option in patients who experience hypersensitivity reactions with conventional paclitaxel (Table 1) (Yamamoto et al., 2011) .
Finally, there are some data for taxane rechallengerechallange combined with targeted therapy. The phase III AVADO trial of bevacizumab plus docetaxel as first-line therapy for MBC included a small percentage of patients pretreated with adjuvanta taxane (Miles et al., 2010) . Although response rate and PFS were significantly superior in the bevacizumab arm, the combination did not improve OS and is not, therefore, approved by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) for MBC. Similarly, the CLEOPATRA clinical trial combined trastuzumab and docetaxel with pertuzumab or placebo as first line for HER-2 positive MBC included 23.2% and 22.6% of patients pretreated with taxanes (Swain et al., 2015) . Recently reported positive OS results have established the triplet as the recommended first-line treatment of choice for women with HER2-positive MBC.
Capecitabine
Capecitabine, usually given as monotherapy, is commonly used in patients with anthracycline-and taxane-refractory or −resistant MBC, having been extensively evaluated in phase II trials in pretreated MBC and to a lesser extent in randomized trials (Blum et al., 1999; Blum et al., 2001; O'shaughnessy et al., 2001; Talbot et al., 2002; Reichardt et al., 2003; Fumoleau et al., 2004; Blum et al., 2007b; Miller et al., 2005) . In a 2011 systematic review of trials in which at least 80% of patients had received prior anthracycline and taxane, 1494 patients from 8 randomized phase II trials and 2 phase III trials were treated with single-agent capecitabine; the response rate was 18%, median PFS 4.2 months, and OS 13.5 months (Oostendorp et al., 2011) . Results from more recent phase III trials of capecitabine monotherapy as the control arm in similar populations reported comparable outcomes (Thomas et al., 2007a; Sparano et al., 2010; Kaufman et al., 2015; Baselga et al., 2014) . For historical reasons, most capecitabine trials in MBC are from molecularly-unselected populations. Recent data suggest that capecitabine may be more active in patients with HR-positive MBC (Glück et al., 2009 ). Experience with capecitabine-based combinations has been mixed. The addition of capecitabine to docetaxel improves OS vs docetaxel alone, but at the cost of greater toxicity (O'shaughnessy et al., 2002) . Although this is one of the few regimens that significantly improve OS in MBC, and does so without sacrificing QOL, the combination was not widely adopted in clinical practice due to concerns over toxicity. The addition of ixabepilone to capecitabine increased ORR and PFS, but not OS, and caused substantially more neuropathy and neutropenia (Table 3) (Thomas et al., 2007a; Sparano et al., 2010) . Nevertheless, the combination of capecitabine and ixabepilone was approved by the FDA but not by the EMA. Despite initial encouraging results with the combination of capecitabine and sorafenib, a subsequent double-blind, placebocontrolled phase III trial in patients with previously-treated MBC comparing the combination with single-agent capecitabine failed to meet its primary endpoint of improved PFS 515 Finally, a phase II study of capecitabine and eribulin in 42 patients with previouslytreated MBC reported an ORR of 42% and PFS of 7.2 months; this efficacy was almost identical to that previously reported with capecitabine and docetaxel, but with superior tolerability and no unexpected toxicities (Twelves et al., 2014a) . Of note, the median number of cycles was 8 (range 1-46) and seven patients (16.2%) received >30 cycles of the combination.
Newer antimicrotubule agents

Ixabepilone
The epothilones are structurally distinct from taxanes and represent a new class of microtubule inhibitors; importantly, they have preclinically promising activity in taxane-resistant tumors (Table 3 ) (Thomas et al., 2007a; Sparano et al., 2010; Perez et al., 2007; Thomas et al., 2007b; Aogi et al., 2013; Smith et al., 2013) . Ixabepilone, a semi-synthetic analog of epothilone B, is the first epothilone to be approved by the FDA as a single agent after failure of anthracycline, taxane, and capecitabine; it was also approved by the FDA in combination with capecitabine in patients with previouslytreated MBC as described above. Ixabepilone has not, however, been approved by the EMA due to concerns about its therapeutic index, especially the risk of neuropathy (European Medicines Agency, 2014) . Some support for the combination of ixabepilone and capecitabine comes from a pre-planned pooled analysis of 2 trials (Thomas et al., 2007a; Sparano et al., 2010) , in which patients with TNBC (n = 443) had superior ORR (31% vs 15%), longer PFS (4.2 vs 1.7 months), and a trend toward longer survival (10.3 vs 9.0 months) vs single-agent capecitabine (Rugo et al., 2008) .
In an attempt to improve its therapeutic index in MBC, the standard 3-weekly regimen of ixabepilone was compared to weekly treatment (days 1, 8, 15 every 28 days); 3-weekly ixabepilone was more effective than weekly treatment, albeit with considerably more toxicity and patient withdrawals due to toxicity (Smith et al., 2013) . In the first-line setting, a large randomized trial comparing 3-weekly ixabepilone to weekly paclitaxel and weekly nab-paclitaxel, each combined with bevacizumab, closed recruitment to the ixabepilone arm at the first interim analysis when the comparison of ixabepilone vs paclitaxel crossed the boundary for futility (Table 2) (Rugo et al., 2015) . Ixabepilone was significantly less effective than paclitaxel (median PFS 7.6 vs 10.6 months, respectively; hazard ratio (HR), 1.53 [95% CI, 1.24-1.90]; p < 0.0010); weekly paclitaxel caused less peripheral sensory neuropathy (16% and 25%, respectively) but more grade 3/4 neutropenia (47% and 7% with paclitaxel and nab-paclitaxel, respectively). Questions remain, including whether the regimens chosen (based on phase II trials) were optimal; whether toxicity and consequent dose reductions (45% of patients in the nab-paclitaxel arm) account for reduced efficacy; and whether bevacizumab may have had a differential effect between the treatment arms. Overall, the role of ixabepilone as single agent or combined with capecitabine as treatment of MBC remains unclear and the risk-benefit balance challenging.
Eribulin
A more significant addition to the list of novel agents for the treatment of chemotherapy-resistant/pretreated MBC is eribulin mesylate. As a structurally simplified synthetic analog of the natural marine product halichondrin B, eribulin distinguishes itself from other antimicrotubule agents by its unique interaction with tubulin, inhibiting microtubule growth with no apparent effect on depolymerization, unlike other cytotoxic agents directed at the microtubule (Kuznetsov et al., 2004) . This novel mechanism of action may explain the activity of eribulin in taxane-resistant tumor cell lines (Kuznetsov et al., 2004) . Encouraging activity was seen in an initial phase II study, but at the price of frequent neutropenia leading to frequent dose omissions (Vahdat et al., 2009 ). Modification of the regimen from administration on days 1, 8, and 15 every 28 days to a days 1 and 8 every 21-day regimen reduced treatment omissions and maintained activity, although neutropenia remained common (Vahdat et al., 2009; Cortes et al., 2010) .
The global multicenter phase III trial, EMBRACE (Eisai Metastatic BReast Cancer study Assessing physician's Choice vs E7389) randomized patients with locally recurrent or MBC previously treated with 2-5 prior chemotherapy regimens, including anthracycline and taxane, to eribulin or single-agent "treatment of physicians' choice" (TPC) (Cortes et al., 2011) . The study achieved its primary endpoint with a statistically and clinically significant increase in OS of 2.5 months with eribulin; TTP and ORR supported the clinical benefit of eribulin over TPC. The most common grade 3-4 toxicities were neutropenia, although febrile neutropenia was uncommon (8% of patients), as was reversible peripheral neuropathy (Table 3 ). An updated survival analysis after 77% of events, requested by regulators, confirmed the primary analysis with eribulin benefits being maintained across all molecular subtypes of MBC. EMBRACE established eribulin as the only cytotoxic to significantly prolong survival in patients with MBC previously treated with both anthracycline and taxane and led to its approval as third-line or later treatment in this setting. The novel study design, with a TPC control arm and OS primary endpoint, was commended by the FDA (Donoghue et al., 2012) .
A second phase III trial, Study 301, compared eribulin with capecitabine in a less heavily pretreated population, who had nevertheless received anthracycline and taxane (Kaufman et al., 2015) .The trial failed to meet its co-primary endpoints of improved OS, although there was a trend favoring eribulin (HR 0.88 [95% CI, 0.77-1.00]; p = 0.056). Neutropenia was common, but febrile neutropenia was seen even less frequently (<3%) than in the EMBRACE trial; QOL was similar in both arms (Cortes et al., 2015a,b) . Of note, there was no difference in PFS between the two arms. Recent preclinical work has suggested that eribulin may alter tumor biol- ogy in other ways by remodeling the tumor vasculature, reversing epithelial-mesenchymal transition and decreasing the capacity of tumor cells for migration and invasion (Yoshida et al., 2014) . These non-classical effects may explain, at least in part, the greater effect of eribulin on OS than PFS or response rates. The EMA recently requested a joint analysis of the two phase III trials that enabled a more detailed evaluation of eribulin in various subgroups. OS was prolonged by 2.4 months (HR 0.85 [CI, ; p = 0.003) (Twelves et al., 2014b) . The benefits of eribulin were maintained across subgroups, but were most robust in patients with HER2-negative disease and appeared greatest in patients with TNBC who gained an average of almost 5 months in OS (HR 0.74 [CI, ; p = 0.006). Subsequently, the EMA widened the approval for eribulin, moving it to the second-line setting. The combination of eribulin and capecitabine also appears to be highly effective and remarkably well tolerated as described above (Twelves et al., 2014a) .
Emerging new agents
Capecitabine and eribulin are currently the "go to" agents for MBC after anthracycline and taxane. Preliminary reports of pivotal studies with etirinotecan pegol and vinflunine have been presented and full publications are awaited (Table 1) .
Vinflunine
Vinflunine is a third-generation, fluorinated vinca alkaloid that has been studied in patients with MBC after first-line anthracyclineand taxane-based chemotherapy. In phase II trials, ORRs ranged from 12.5% to 30%, median PFS from 2.6 to 3.7 months, and OS from 11 to 14 months (Campone et al., 2006; Fumoleau et al., 2009) . Tolerability was reported as acceptable; nevertheless, almost two-thirds of patients, experience grade 3/4 neutropenia. In a preliminary report of a large phase III trial single agent vinflunine did not, however, improve survival compared to an alkylator of physician's choice (9.1 and 9.3 months, respectively) (Cortes et al., 2015b) .
Two recent MBC trials have assessed vinflunine in combination with capecitabine or gemcitabine (Aapro et al., 2014; Jimenez et al., 2014; Llombart et al., 2014) . The addition of vinflunine to capecitabine in women with MBC previously treated with or resistant to an anthracycline and a taxane prolonged PFS by 1.3 months; this improvement was statistically significant and associated with less hand-foot syndrome but grade 3 or 4 neutropenia was increased with the combination (Table 1) (Aapro et al., 2014; Jimenez et al., 2014) . Vinflunine was also investigated as an alternative to paclitaxel in combination with gemcitabine as first-line treatment for patients previously receiving anthracycline (Llombart et al., 2014) . Non-inferiority with respect to PFS was demonstrated for the vinflunine combination (HR 1.05), which was also less neurotoxic than the paclitaxel-gemcitabine combination. There was, however, no difference in OS (19.1 months and 18.9 months, respectively).
Vinflunine has not been approved by the regulatory authorities for use in MBC.
Etirinotecan pegol (NKTR-102)
Topoisomerase I (TOP1) inhibitors disrupt DNA replication in cancer cells causing single strand, and eventually lethal double strand, DNA breaks leading to cell death (Xu and Villalona-Calero, 2002) . TOP1 inhibition is a "validated" target but has been studied only to a limited extent in MBC (Kumler et al., 2013) . TOP1 inhibitors have a mechanism of action distinct from, and lack crossresistance with, cytotoxic agents currently used to treat MBC. No topoisomerase I inhibitors have been approved by the FDA or EMA for the treatment of breast cancer.
In a systematic review of TOP1 inhibitors in 4 trials of 217 patients with refractory MBC treated with single-agent irinotecan, ORR ranged from 5% to 23%; primary grade 3/4 toxicities were neutropenia, diarrhea, and nausea/vomiting (Kumler et al., 2013) . Much of the toxicity associated with irinotecan is due to high peak drug concentrations with 3-weekly dosing (Gerrits et al., 1997) . This was reflected in a randomized phase II MBC trial in which weekly irinotecan 100 mg/m 2 appeared better tolerated and more active (ORR 23%; median PFS, 2.8 months) than every 3-weekly treatment at a dose of 240 mg/m 2 (ORR 14%; median PFS, 1.9 months) (Perez et al., 2004) . This suggests that prolonged exposure to irinotecan, and its active metabolite SN38, might be beneficial.
Etirinotecan pegol is a long-acting polymer-engineered molecule comprising irinotecan bound to a proprietary polyethylene glycol core by a biodegradable linker that slowly hydrolyzes in vivo to release SN38, the active moiety of irinotecan (Jameson et al., 2013; Hoch et al., 2014) . Etirinotecan pegol is designed to provide continuous exposure to SN38 at the site of the tumor through altered pharmacokinetics and by exploiting the enhanced permeability and retention (EPR) effect. The principle is that the high molecular weight of the parent drug will limit its ability to freely cross the intact vasculature into healthy tissues; however, because of the EPR effect in tumors, the macromolecule should easily traverse the leaky tumor vasculature.
Pharmacology
Preclinical and initial clinical studies demonstrated a marked contrast in the pharmacokinetic profile of SN38 after treatment with etirinotecan pegol compared to irinotecan (Jameson et al., 2013; Hoch et al., 2014) . Eritinotecan pegol achieved a maximum plasma concentration (Cmax) of SN38 10-fold less than irinotecan but the half-life of SN38 was much longer (50 days and 12-17 h for etirinotecan and irinotecan, respectively) (Jameson et al., 2013) . These pharmacokinetic characteristics would be expected to reduce toxicities associated with the excessively high SN38 concentrations but maintain efficacy with tumor exposure to SN38 throughout the treatment cycle. This was confirmed in preclinical models with etirinotecan pegol achieving higher and more sustained tumor concentrations of SN38 that correlated with greater tumor growth inhibition in comparison to irinotecan . Interestingly, etirinotecan pegol penetrates, and is retained in, TNBC brain metastases (Nounou et al., 2014) ; there was a significant reduction in both the size and number of brain metastases, and etirinotecan pegol-treated animals had prolonged survival . These results are notable given the efficacy of etirinotecan pegol in patients with brain metastases in the BEACON trial (see below).
Early clinical trials
Phase I trials of etirinotecan pegol revealed early evidence of antitumor activity, including in MBC, over multiple dosing schedules with significantly different toxicity compared to irinotecan . A subsequent open-label randomized phase II trial evaluated etirinotecan pegol 145 mg/m 2 every 2 weeks (q14d) or every 3 weeks (q21d) in patients failing prior taxane and receiving ≤2 previous chemotherapy regimens for MBC (Awada et al., 2013) . The primary endpoint was ORR. Ten of 35 patients in each arm responded, with an ORR in the intention-to-treat (ITT) population of 29% (95% CI 18.4-40.6). The median PFS was 4.7 months (ITT population; 95% CI, 2.7-5.7 months), with more than a third of patients (35.5%) progression-free at 6 months. Delayed diarrhea was the most common serious toxicity (q14d: 69% all grades, 17% grade 3, 3% grade 4; q21d: 77% all grades, 23% grade 3, no grade 4) and typically occurred after 3 months of therapy. Unfortunately, diarrhea management and dose reduction guidelines were not followed appropriately in more than half (59%) of patients. Other grade 3/4 toxicities observed in >10% of patients across both schedules included fatigue (11%), dehydration (10%), and neutropenia (11%); febrile neutropenia occurred in 1 patient. Comparing the two etirinotecan pegol schedules, both PFS and OS were superior with the q21d schedule (Table 3) , which was also associated with less drug-related ≥ grade 3 toxicity and fewer treatment discontinuations. The q21d schedule was, therefore, selected for further study.
The BEACON trial
First results of the phase III BEACON study (BrEAst Cancer Outcomes with NKTR-102) comparing etirinotecan pegol with TPC (defined as active single agent, consisting of eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel) in 852 patients with MBC who previously received an anthracycline, taxane, and capecitabine were recently reported (Perez et al., 2015) . Stratification factors included geographic region, prior use of eribulin, and receptor status. The primary endpoint was OS; additional endpoints were PFS, ORR, clinical benefit rate, duration of response, pharmacokinetics, safety, health-related QOL, and pharmacoeconomics. Additionally, key exploratory endpoints included specific biomarkers (TOP1, topoisomerase 2, markers of DNA damage/apoptosis) in circulating tumor cells (CTCs) using ApoCell technology (Hoch et al., 2013) ; prespecified analyses also include efficacy assessments in poor prognostic subgroups (i.e., those with liver and/or stable brain metastases at study entry).
Although median survival was longer in the etirinotecan arm by 2.1 months (12.4 months and 10.3 months, respectively; HR 0.87, P = 0.08), the trial did not meet its primary endpoint. Among the prespecified subgroup of 67 patients with preexisting stable brain metastases, there appeared to be particular OS benefit from etirinotecan pegol (10.0 and 4.8 months, respectively; HR 0.51, P < 0.01), and 12-month survival was 44.4% and 19.4%, respectively. Similarly, the group with liver metastasis (n = 456) also benefited significantly from etirinotecan pegol (OS 10.9 and 8.3 months, respectively; HR 0.73, P < 0.002) (Perez et al., 2015) . Analyses of subgroups defined by baseline CTC biomarkers are awaited.
Conclusions
Chemotherapy remains a mainstay of treatment for patients with MBC treatment, regardless of the molecular phenotype. Following anthracycline and taxane treatment many patients remain candidates for further chemotherapy. Despite the number of cytotoxic agents available to clinicians, there exists a limited amount of evidence-based randomized data and hence, uncertainty and a lack of consensus on the optimal sequence of agents. Nevertheless, a systematic approach is helpful for identifying which agents may be utilized under what circumstances (Fig. 1) .
Notwithstanding the emergence of newer targeted therapies and the emerging promise of immunotherapy, we argue that it would be premature to abandon attempts to develop new cytotoxic chemotherapy for the treatment of patients with MBC. On the other hand, new cytotoxic agents should not be "me too" therapies. Rather, new cytotoxic agents should address specific challenges: (1) either a novel target, a novel interaction with an established target, or a novel mode of delivery; (2) achieve meaningful improvements in clinically relevant endpoints, preferably OS and/or QOL, in well-designed randomized phase III trials; and, (3) ideally should identify biomarker(s) predictive of benefit or resistance.
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